Work

New hemiaminal ether dihydropyrimidinones as CK1/CK2 inhibitors targeting α-synuclein in Parkinson's disease

Year: 2026

Type: article

Abstract: values of 9.3, 1.69, and 6.0 µM, respectively. Favorable ADMET and pharmacokinetic profiles supported the synthesized DHPM (3a-3h) derivatives as promising leads for inhibiting kinase activity (CK1/CK2) and preventing ASN aggregation in Parkinson's disease.

Source: RSC Advances

DOI: 10.1039/d6ra06901k

Authors: Hamza Wakeel, Shanza Munir, Humaira Yasmeen Gondal, Zain Maqsood Cheema, Aleena Muskan, Imran Malik, Muhammad Nisar, Hina Siddiqui, Sadaf Khaliq Sultan

Institutions: University of Education, University of Sargodha, Riphah International University, University of Karachi, International Center for Chemical and Biological Sciences

Language: English

Topic: Parkinson's Disease Mechanisms and Treatments

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,042

OpenAlex ID: W7225129100

FWCI:

Cites: 60

Cited by:

Related to: 10